There are currently 523 clinical trials in Tucson, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Arizona, Banner University Medical Center - Tucson, Arizona Cancer Center and University of Arizona Cancer Center-North Campus. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
NCT04820179
Recruiting
Pancreatic cancer is one of the leading causes of cancer deaths in the United States with limited treatment options, especially for those patients with metastatic disease. Combination treatment with cabozantinib and atezolizumab, has demonstrated safety for the treatment of other cancers and has shown promise in preclinical studies utilizing patient derived pancreas organoids. In this study, patients with refractory, metastatic pancreatic cancer will receive combination cabozantinib + atezolizum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: Pancreatic Cancer, Metastatic Pancreatic Cancer
Register for Updates
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University of Arizona, Health Sciences Center, Tucson, Arizona
Conditions: Focal Onset Seizures
Register for Updates
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/27/2025
Locations: University of Arizona - Health Science Center, Tucson, Arizona
Conditions: Primary Generalized Tonic-Clonic Seizures
Register for Updates
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
NCT06016088
Recruiting
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/27/2025
Locations: Tucson Cystic Fibrosis Center, Tucson, Arizona
Conditions: Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Register for Updates
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
NCT06613360
Recruiting
Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/26/2025
Locations: Cullinan Investigative Site, Tucson, Arizona
Conditions: SLE, SLE (Systemic Lupus)
Register for Updates
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT04340141
Recruiting
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +1 locations
Conditions: Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
Register for Updates
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
06/24/2025
Locations: Banner Alzheimer's Institute Tucson, Tucson, Arizona +1 locations
Conditions: Alzheimer Disease
Register for Updates
Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
NCT06394830
Recruiting
This is an open-label study that will enroll participants with Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). The study will assess PRN (as needed) dosing of up to 6 intravesical (via catheter) doses of VNX001 (study drug) to treat acute instances of moderate to severe bladder pain over a 14-day period. The main aim of the study is to tally the number of doses and assess pain before and after doses. The study will review the safety and tolerability of VNX001. Participants will need to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Arizona Urology Specialists, Tucson, Arizona
Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Register for Updates
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
NCT06450106
Recruiting
A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Arizona Urology Specialists, Tucson, Arizona
Conditions: Prostate Cancer
Register for Updates
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
NCT06632977
Recruiting
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. Valemetostat tosylate is in a class of medications called EZH1/EZH2 inhibitors. It blocks proteins called EZH1 and EZH2, which may help slow or stop the sprea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +1 locations
Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289
Recruiting
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
06/24/2025
Locations: Research Site, Tucson, Arizona
Conditions: Eosinophilic Asthma
Register for Updates
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
NCT06859294
Recruiting
The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/24/2025
Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast, Tucson, Arizona
Conditions: Rheumatoid Arthritis
Register for Updates